BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Osteoarthritis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Osteoarthritis\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07580716-106@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Allocetra: Phase 2 readout est. (NCT07580716)
DESCRIPTION:Allocetra\, phase 2\, Osteoarthritis.\nStudy: Intra-Articular A
 llocetra in Patients With Primary Knee Osteoarthritis\nEstimated primary c
 ompletion: February 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/allocetra#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07580716
URL:https://assetmemo.bio/drug/allocetra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07353931-278@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:eloralintide: Phase 3 readout est. (NCT07353931)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: Efficacy and Safety o
 f Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain a
 nd Obesity or Overweight\nEstimated primary completion: March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/eloralintide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07353931
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153471-117@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07153471)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Participants With Obesity or Overweight and O
 steoarthritis (OA) of the Knee\nEstimated primary completion: April 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07153471
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734311-193@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:ecnoglutide: Phase 3 readout est. (NCT07734311)
DESCRIPTION:ecnoglutide\, phase 3\, Obesity.\nStudy: A Study of Econoglutid
 e Injection in Obese Participants With Knee Osteoarthritis (KOA)\nEstimate
 d primary completion: 31 May 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ecnoglutide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07734311
URL:https://assetmemo.bio/drug/ecnoglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
